


Herpesviruses

By
S.Sravanthi
Asst Professor

Structure and Composition

- Spherical iscoahedron, 150-200 nm
- Double-stranded DNA, linear
- More than **35 proteins**
- Enveloped
- **Replication from nucleus** (budding)
- Features
 - Encode **many enzymes**
 - Establish **latent** infections
 - **Lifelong persistence**
 - Significant **cause of death** in immunocompromised hosts
 - Some can cause cancers



Classification (human viruses)

Subfamilies

- Alpha
- Beta
- Gamma

Species

- Simplex 1 (HHV-1) (alpha)
- Simplex 2 (HHV-2) (alpha)
- Varicella (HHV-3) (alpha)
- Epstein-Barr (HHV-4) (gamma)
- Cytomegalovirus (HHV-5) (beta)
- HHV-6 (beta)
- HHV-7 (beta)

Replication of HSV

Virus attachment and membrane fusion

Viral host shutoff (VHS) protein released into the cytoplasm and initiates the degradation of host cell mRNA

α -Trans-inducing factor (α TIF) is transported to the nucleus

Capsid travels to nucleus where viral DNA is released, enters a nuclear pore and **circularizes**

α TIF induces the expression of viral **alpha genes**

The mRNAs for the alpha genes are translated on ribosomes

The proteins then enter the nucleus and express the viral **beta genes**


The beta proteins are involved in **degrading cellular chromatin** and localizing cellular DNA to the inner side of the nuclear envelope (**marginination**)

Viral DNA is replicated as **concatemers**

Gamma proteins (structural) are expressed

Nuclear escape

- Viral proteins induce budding of the capsid through **both** nuclear membranes
- Thus, capsid escapes into the cytoplasm
- Viral proteins associate with the cellular vesicles
- These proteins have affinity for the capsid proteins and cause the vesicle to **wrap around the virus**, providing it with an **double-layered envelope**
- Virus traverses the ER then Golgi prior to release from the cell
 - The **outer membrane** fuses with the plasma membrane



Herpes Simplex viruses

Two species

- HSV-1: oropharyngeal sores (children)
- HSV-2: genitalia (young adults)

Highly similar genomes, but distinct

- 150 kb
- 70+ polypeptides

Virulence factors

- gC binds complement C3b
- gE is an Fc receptor for IgG

Herpes simplex viruses (cont.)

Pathology

- Wide **cellular tropism**
- Most common to dermal tissues (herpetic lesions)

- Cell fusion **followed by cell lysis**
- Inflammatory response

Transmission

- Generally through direct contact with person **shedding virus**
 - Some people shed virus **despite absence of lesions**
- Virus enters through **mucosal tissues**; cannot penetrate healthy skin

Latent infections

- Virus sequesters in nerve tissues (**immunoprivileged site**)
 - HSV-1 in **trigeminal ganglia**
 - HSV-2 in **sacral ganglia**
- Very few genes are expressed by infected cells

Herpes simplex viruses (cont.)

- Clinical conditions

- Oropharangeal disease

- Symptoms: fever, **vesicular and ulcerative lesions**, edema, gingivostomatitis, lymphadenopathy, malaise
- Recurrence in some people throughout adult life

- Keratoconjunctivitis

- Inadvertent **self-transmission** (aka, **autoinoculation**) to eye
- Causes lesions
- Scarring can cause vision impairment
- Can lead to an **autoimmune response against the eyes**

- Genital herpes

- Similar lesions and recurrence
- Complications can occur
 - Transmission to newborn infant

- Acute retinitis

Herpes simplex viruses (cont.)

Clinical conditions

• Skin infections

- Documented in **laboratory or health care workers** with compromised skin
- Persons with skin diseases can have serious infections

• Encephalitis

- **HSV-1** is most common cause (proximity to brain)
- High fatality rate in untreated patients (70%)
- Survival is often accompanied by **permanent neurological disorders**

• Neonatal herpes

- Transmission: in utero, during birth, after birth
- High fatality rate if untreated (50%)

• Immunocompromised hosts

- Systemic infections

Immunity

Immune response is **not sterilizing**

- IgG, IgA, IgM
- CTL responses are **impaired**
 - Viral proteins block MHC class I pathway
 - **$\alpha 47$** protein retains class I molecules in the cytoplasm
 - **ICP47** protein inhibits peptide translocation into the ER lumen
 - CD4⁺ T cells act as CTL to kill infected cells
 - Cannot engage ganglia cells

Laboratory Diagnosis

Cytopathology

- **Multinucleated giant cells** from skin scrapings

Virus isolation

- Immunofluorescence
- Restriction digestion of viral DNA (HSV-1 vs. HSV-2)

PCR

- Used for **systemic or encephalitic** disease

Serology

- IgG appears in 4-7 days
- **Cannot discriminate** HSV-1 from HSV-2

Epidemiology

Global

HSV-1

- Most commonly acquired by **children**
- Most adults are seropositive
- Only a small proportion have recrudescence

HSV-2

- Most commonly acquired by **young adults**
 - Sexually-transmitted disease
- About **1 in 6** Americans has HSV-2
- Fetal/newborn transmission
- **Increased risk** for HIV infection

reatment, prevention and control

heomtherapy


• **Acyclovir** drug of choice

• Nucleoside analog

- Phosphorylated by HSV **thymidine kinase**
- Then converted into Acy-triphosphate by cellular kinases
- Incorporated into newly-synthesized HSV DNA and acts as a **chain-terminator**

• Dramatic impact on **reduction of transmission** and **survival** of neonatal, visceral and encephalitic HSV infections

• **No vaccine** is available



Varicella-Zoster virus

- **Varicella** (“chickenpox”)
- **Zoster** (“shingles”)
- Pathogenesis
 - Varicella
 - **Respiratory transmission**
 - Replication in **regional lymphoid** tissue (e.g. mediastinal LN)
 - Viremia
 - Infected **mononuclear cells** take virus to skin where lesions form
 - Virus sequesters in **ganglia**
 - Immunity is usually life-long
 - Zoster
 - Recurrence of virus in adults



Varicella-Zoster virus

- Clinical spectrum
 - Almost always apparent
 - 10-21 day incubation
 - Malaise, fever, rash for about 5 days
 - Complications are rare
 - Ocular infections can lead to impaired vision
 - Primary infection as an adult is usually more serious
 - Before vaccine, about 10 people died each year in the U.S.
 - Immunocompromised patients
- Zoster
 - Usually occurs in aged or immunodeficient persons
 - Often starts as lesions on the lower back
 - Painful

Laboratory diagnosis

- Usually not necessary except for immunocompromised
- Virus isolation in **human embryonic cells**
- Serology

Epidemiology

- Worldwide
- Most children by age 10 (varicella)
- Occasionally in adults (zoster)

Treatment

- No treatment required for healthy persons (except eye infections)
- Immunocompromised patients can get **immune globulin** (passive immunization)
 - Acyclovir

Vaccination

- Vaccine approved for use in the U.S. in 1995
- Now recommended for children (MMRV tetravalent)
- Vaccination resulted in
 - Fewer hospitalizations
 - Savings of **hundreds of millions of dollars** in hospital expenses per year

Cytomegalovirus

- Largest genome of the human herpesviruses
- IE promoter is driven by **cellular transcription factors**

Pathogenesis

- Usually **asymptomatic**
- Can cause a **mononucleosis-like disease**
- Viremia leads to wide tissue distribution
- Immunocompromised hosts can have serious **pneumonia**
- **Congenital/perinatal infections**
 - About 1% of children in U.S. will be infected with CMV at birth
 - Of these, about 5-10% will have **developmental defects**

Clinical spectrum

- Usually mild disease
- Immunocompromised can develop **systemic disease**

Immunity

- IgM, IgG, IgA
- Virus becomes latent with episodes of recurrence

Laboratory diagnosis

- PCR is method of choice
- Virus isolation is slow - **two to three weeks** before CPE
- Serology is usually not informative

Epidemiology

- Worldwide
- Humans are only known host
- Transmission through close contact (oral/respiratory routes)

Treatment

- Ganciclovir for life-threatening infections

Epstein-Barr virus


- Around 100 genes
- Targets B cells
 - Can also infect epithelial cells of oropharynx, parotid gland, cervix
- Binds to **complement receptor 2** (CR2; aka, **CD21**)
- Usually becomes **latent** in the B cell
 - Fewer than 10% of infected cells in vitro release virus
- Can cause transformation
 - Used to make immortalized human B cells that secrete **monoclonal antibodies**

Pathogenesis

- Transmission through saliva
- Initial replication in epithelial cells
- B cells in lymphoid tissues

Clinical spectrum

- Infectious mononucleosis
 - Lengthy incubation period of up to **50 days**
 - Sore throat, fever, malaise,
 - Prolonged recovery
- **Oral hairy leukoplakia** in HIV patients (epithelial cells)
- **Burkitt's lymphoma**
 - Tumor of jaw area of lymphoid tissues
 - Most tumors express viral EBNA1
 - Correlates with **malaria infections**
 - **Chromosomal translocations**



Laboratory diagnosis

- PCR
- Virus isolation (slow)
- Serology is not useful

Epidemiology

- Worldwide

Prevention and control

- No vaccine available
- Acyclovir has no effect

Other herpesviruses

- HHV-6
 - Infects T cells
 - Causes roseola
 - Only a problem in immunocompromised patients
- HHV-7
 - Infects T cells
 - No known disease
- HHV-8
 - Kaposi's sarcoma virus
 - Before HIV disease, only known to cause disease in men of Mediterranean descent and chemotherapy patients



Herpes B virus

- Formerly known as Herpes simiae
- Officially known as cercopithecine herpesvirus 1
- Almost always fatal in humans
 - Has high propensity for **central nervous system** and causes **substantial damage**
 - Survivors usually have **neurological disorders**
- No effective treatment